collection
MENU ▼
Read by QxMD icon Read
search

Rheumatoid Arthritis

shared collection
94 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28217871/secukinumab-in-active-rheumatoid-arthritis-a-randomized-double-blind-placebo-and-active-comparator-controlled-phase-3-study
#1
Francisco J Blanco, Rüdiger Möricke, Eva Dokoupilova, Christine Codding, Jeffrey Neal, Mats Andersson, Susanne Rohrer, Hanno Richards
OBJECTIVE: To evaluate the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response or intolerance to tumor necrosis factor inhibitors (TNF-inhibitors). METHODS: In this phase 3 study, 551 patients were randomized (1:1:1:1) to receive intravenous secukinumab 10 mg/kg (baseline, weeks 2, 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks or abatacept or placebo at the same dosing schedule...
February 19, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28245350/cardiovascular-safety-of-tocilizumab-versus-tumor-necrosis-factor-inhibitors-in-patients-with-rheumatoid-arthritis-a-multi-database-cohort-study
#2
Seoyoung C Kim, Daniel H Solomon, James R Rogers, Sara Gale, Micki Klearman, Khaled Sarsour, Sebastian Schneeweiss
OBJECTIVE: While tocilizumab (TCZ) is known to increase LDL cholesterol, it is unclear whether TCZ increases cardiovascular (CV) risks in patients with rheumatoid arthritis (RA). METHODS: To examine comparative CV safety, we conducted a cohort study of RA patients who newly started TCZ or TNFi using claims data from Medicare, IMS PharMetrics and MarketScan. All patients were required to have previously used a different TNFi, abatacept, or tofacitinib. The primary outcome was a composite CV endpoint of hospitalization for myocardial infarction (MI) or stroke...
February 28, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28153828/clinical-benefit-of-1-year-certolizumab-pegol-czp-add-on-therapy-to-methotrexate-treatment-in-patients-with-early-rheumatoid-arthritis-was-observed-following-czp-discontinuation-2-year-results-of-the-c-opera-study-a-phase-iii-randomised-trial
#3
Tatsuya Atsumi, Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Shinsuke Yasuda, Yuji Yamanishi, Yasuhiko Kita, Tsukasa Matsubara, Masahiro Iwamoto, Toshiharu Shoji, Osamu Togo, Toshiyuki Okada, Désirée van der Heijde, Nobuyuki Miyasaka, Takao Koike
OBJECTIVES: To investigate the clinical impact of 1-year certolizumab pegol (CZP) therapy added to the first year of 2-year methotrexate (MTX) therapy, compared with 2-year therapy with MTX alone. METHODS: MTX-naïve patients with early rheumatoid arthritis (RA) with poor prognostic factors were eligible to enter Certolizumab-Optimal Prevention of joint damage for Early RA (C-OPERA), a multicentre, randomised, controlled study, which consisted of a 52-week double-blind (DB) period and subsequent 52-week post treatment (PT) period...
February 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28213564/seven-year-tolerability-profile-of-glucocorticoids-use-in-early-rheumatoid-arthritis-data-from-the-espoir-cohort
#4
Camille Roubille, Nathalie Rincheval, Maxime Dougados, René-Marc Flipo, Jean-Pierre Daurès, Bernard Combe
OBJECTIVE: To explore the 7-year tolerability profile of glucocorticoids (GC) for early rheumatoid arthritis (RA). METHODS: We examined data for 602 patients with RA from the early arthritis Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) cohort (<6 months disease duration) stratified into two groups: with or without GC treatment at least once during follow-up (median 7 years (IQR 0.038-7.65)). The main outcome was a composite of death, cardiovascular disease (including myocardial ischaemia, cerebrovascular accident and heart failure), severe infection and fracture...
February 17, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28298374/safety-of-synthetic-and-biological-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-management-of-rheumatoid-arthritis
#5
Sofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, Jackie L Nam, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, Johannes W Bijlsma, Gerd R Burmester, Marieke Scholte-Voshaar, Louise Falzon, Robert B M Landewé
OBJECTIVES: To assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform the European League Against Rheumatism recommendations for the management of RA. METHODS: Systematic literature review (SLR) of observational studies comparing any DMARD with another intervention for the management of patients with RA. All safety outcomes were included. A comparator group was required for the study to be included...
March 15, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28283512/efficacy-of-biological-disease-modifying-antirheumatic-drugs-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-rheumatoid-arthritis
#6
Jackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, Katerina Chatzidionysiou, Josef S Smolen, Désirée van der Heijde, Johannes W Bijlsma, Gerd R Burmester, Maxime Dougados, Marieke Scholte-Voshaar, Ronald van Vollenhoven, Robert Landewé
OBJECTIVES: To update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations. METHODS: MEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained...
March 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28219691/hepatitis-b-reactivation-associated-with-immune-suppressive-and-biological-modifier-therapies-current-concepts-management-strategies-and-future-directions
#7
REVIEW
Rohit Loomba, T Jake Liang
Hepatitis B reactivation associated with immune suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with current or prior exposure to hepatitis B virus infection. The population at risk for HBV reactivation includes those who are either currently infected with HBV or have past exposure to HBV. Since curative and eradicative therapy for HBV is not currently available, there is a large reservoir of individuals at risk for HBV reactivation in the general population...
February 17, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28262700/t-cell-costimulation-blockade-blunts-pressure-overload-induced-heart-failure
#8
Marinos Kallikourdis, Elisa Martini, Pierluigi Carullo, Claudia Sardi, Giuliana Roselli, Carolina M Greco, Debora Vignali, Federica Riva, Anne Marie Ormbostad Berre, Tomas O Stølen, Andrea Fumero, Giuseppe Faggian, Elisa Di Pasquale, Leonardo Elia, Cristiano Rumio, Daniele Catalucci, Roberto Papait, Gianluigi Condorelli
Heart failure (HF) is a leading cause of mortality. Inflammation is implicated in HF, yet clinical trials targeting pro-inflammatory cytokines in HF were unsuccessful, possibly due to redundant functions of individual cytokines. Searching for better cardiac inflammation targets, here we link T cells with HF development in a mouse model of pathological cardiac hypertrophy and in human HF patients. T cell costimulation blockade, through FDA-approved rheumatoid arthritis drug abatacept, leads to highly significant delay in progression and decreased severity of cardiac dysfunction in the mouse HF model...
March 6, 2017: Nature Communications
https://www.readbyqxmd.com/read/28264814/risk-of-serious-infections-associated-with-use-of-immunosuppressive-agents-in-pregnant-women-with-autoimmune-inflammatory-conditions-cohort-study
#9
Rishi J Desai, Brian T Bateman, Krista F Huybrechts, Elisabetta Patorno, Sonia Hernandez-Diaz, Yoonyoung Park, Sara Z Dejene, Jacqueline Cohen, Helen Mogun, Seoyoung C Kim
Objective To compare the risk of serious infections associated with use of systemic steroids, non-biologic agents, or tumor necrosis factor α (TNF) inhibitors in pregnancy.Design Observational cohort study.Setting Public (Medicaid, 2001-10) or private (Optum Clinformatics, 2004-15) health insurance programs in the US.Participants 4961 pregnant women treated with immunosuppressive drugs for rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, or inflammatory bowel disease...
March 6, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28264816/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-and-biological-disease-modifying-antirheumatic-drugs-2016-update
#10
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques-Eric Gottenberg, Johanna M W Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poór, Christophe Richez, Piet van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib)...
March 6, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28148915/therapy-retreatment-with-rituximab-is-beneficial-in-ra
#11
Joanna Collison
No abstract text is available yet for this article.
March 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28250461/the-emerging-safety-profile-of-jak-inhibitors-in-rheumatic-disease
#12
REVIEW
Kevin L Winthrop
Tofacitinib is the first Janus kinase (JAK) inhibitor commercially approved for the treatment of rheumatoid arthritis. This compound and a number of other JAK inhibitors are currently being tested in phase II and III trials for the treatment of a variety of autoimmune inflammatory diseases. Whereas a characteristic safety profile is emerging for some JAK inhibitors, differences between individual agents might emerge on the basis of distinct potency against their molecular targets. Similarly to biological therapy, JAK inhibition can lead to serious and opportunistic infections, and viral infections seem to be particularly frequent...
April 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28202916/rheumatoid-arthritis-new-player-in-ra-pathogenesis-brought-to-light
#13
Joanna Collison
No abstract text is available yet for this article.
April 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28219882/incident-myocardial-infarction-associated-with-major-types-of-arthritis-in-the-general-population-a-systematic-review-and-meta-analysis
#14
Orit Schieir, Cedomir Tosevski, Richard H Glazier, Sheilah Hogg-Johnson, Elizabeth M Badley
OBJECTIVE: To synthesise, quantify and compare risks for incident myocardial infarction (MI) across five major types of arthritis in population-based studies. METHODS: A systematic search was performed in MEDLINE, EMBASE and CINAHL databases with additional manual/hand searches for population-based cohort or case-control studies published in English of French between January 1980 and January 2015 with a measure of effect and variance for associations between incident MI and five major types of arthritis: rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), gout or osteoarthritis (OA), adjusted for at least age and sex...
February 20, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28160488/atherosclerosis-is-not-accelerated-in-rheumatoid-arthritis-of-low-activity-or-remission-regardless-of-antirheumatic-treatment-modalities
#15
Aikaterini Arida, Athanasios D Protogerou, George Konstantonis, Kalliopi Fragiadaki, George D Kitas, Petros P Sfikakis
No abstract text is available yet for this article.
February 4, 2017: Rheumatology
https://www.readbyqxmd.com/read/26962704/rediscovering-the-therapeutic-use-of-glucocorticoids-in-rheumatoid-arthritis
#16
REVIEW
Marlies C van der Goes, Johannes W G Jacobs, Johannes W J Bijlsma
PURPOSE OF REVIEW: This review will focus on new information obtained on how to apply glucocorticoids in the treatment of rheumatoid arthritis, aiming at an optimal risk-benefit ratio. Moreover, advances in the development of new preparations such as liposomal glucocorticoids will be discussed. RECENT FINDINGS: In early rheumatoid arthritis, treatment regimens with a disease-modifying drug and initially medium-dose glucocorticoids (>7.5 but ≤30 mg prednisone equivalent) are noninferior compared with regimens with disease-modifying drugs and initially high-dose glucocorticoids (>30 mg prednisone equivalent) and have repeatedly been proven to be more effective than methotrexate monotherapy...
May 2016: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/28132102/comparative-effectiveness-of-treatment-options-after-conventional-dmards-failure-in-rheumatoid-arthritis
#17
Yoon-Kyoung Sung, Soo-Kyung Cho, Dam Kim, Chan-Bum Choi, Soyoung Won, So-Young Bang, Hoon-Suk Cha, Jung-Yoon Choe, Won Tae Chung, Seung-Jae Hong, Jae-Bum Jun, Hyoun Ah Kim, Jinseok Kim, Seong-Kyu Kim, Tae-Hwan Kim, Hye-Soon Lee, Jaejoon Lee, Jisoo Lee, Shin-Seok Lee, Sung Won Lee, Yeon-Ah Lee, Seong-Su Nah, Chang-Hee Suh, Dae-Hyun Yoo, Bo Young Yoon, Sang Cheol Bae
OBJECTIVE: To compare the clinical effectiveness of two treatment strategies for active rheumatoid arthritis (RA) refractory to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs): starting TNF inhibitors (TNFIs) or changing csDMARDs. METHODS: We used two nationwide Korean RA registries for patient selection. TNFI users were selected from the BIOPSY, which is an inception cohort of RA patients starting biologic DMARDs. As a control group, we selected RA patients with moderate or high disease activity from the KORONA database whose treatment was changed to other csDMARDs...
January 28, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28011918/hepatitis-b-virus-reactivation-in-rheumatoid-arthritis-patients-undergoing-biologics-treatment
#18
Ming-Han Chen, Ming-Huang Chen, Chun-Yu Liu, Chang-Youh Tsai, De-Feng Huang, Hsiao-Yi Lin, Mei-Hsuan Lee, Yi-Hsiang Huang
BACKGROUND: Immunosuppressants can induce hepatitis B virus(HBV) reactivation, however, informative data regarding the risk of different immunosuppressive regimens including biologics on HBV reactivation(HBVr) among patients with rheumatoid arthritis(RA) is unsettled. METHODS: Among 2334 RA patients who had available HBsAg data, 123 patients positive for hepatitis B surface antigen(HBsAg) without receiving anti-HBV prophylaxis were enrolled. These patients undergoing varied mono- or combination immunosuppressive therapy, including 36 receiving biological disease-modifying antirheumatic drugs(bDMARDs)...
December 23, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28129484/perioperative-timing-of-infliximab-and-the-risk-of-serious-infection-after-elective-hip-and-knee-arthroplasty
#19
Michael D George, Joshua F Baker, Jesse Yenchih Hsu, Qufei Wu, Fenglong Xie, Lang Chen, Huifeng Yun, Jeffrey R Curtis
OBJECTIVE: The optimal timing of TNF antagonists before elective surgery is unknown. This study evaluated the association between infliximab timing and serious infection after elective hip or knee arthroplasty. METHODS: A retrospective cohort study evaluated U.S. Medicare patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or ankylosing spondylitis who received infliximab within 6 months of elective knee or hip arthroplasty from 2007-2013...
January 27, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28143815/long-term-safety-of-tofacitinib-for-the-treatment-of-rheumatoid-arthritis-up-to-8-5%C3%A2-years-integrated-analysis-of-data-from-the-global-clinical-trials
#20
Stanley B Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R Curtis, Eun Bong Lee, Peter Nash, Kevin L Winthrop, Christina Charles-Schoeman, Krishan Thirunavukkarasu, Ryan DeMasi, Jamie Geier, Kenneth Kwok, Lisy Wang, Richard Riese, Jürgen Wollenhaupt
OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. METHODS: Data were pooled for all tofacitinib-treated patients (data cut-off: 31 March 2015). Incidence rates (IRs; patients with event/100 patient-years) and 95% CIs are reported for adverse events (AEs) of interest...
January 31, 2017: Annals of the Rheumatic Diseases
label_collection
label_collection
7634
1
2
2017-02-03 10:58:07
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"